To determine whether B cells play any role in generating anti-melanoma immunity in response to checkpoint blockade, tumor-bearing WT and B cell KO mice were treated with anti-PD-L1 or anti-CTLA-4 antibodies. This evidence concerns the gene CTLA4 and neoplasm.